BeiGene, Ltd. (HKG: 6160)

Market Cap	152.41B
Revenue (ttm)	26.04B
Net Income (ttm)	-6.64B
Shares Out	n/a
EPS (ttm)	-63.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	831,366
Open	106.80
Previous Close	106.10
Day's Range	105.20 - 108.30
52-Week Range	75.45 - 153.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10,600
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2023, BeiGene's revenue was 2.46 billion, an increase of 73.65% compared to the previous year's 1.42 billion. Losses were -881.71 million, -56.00% less than in 2022.

Financial numbers in CNY